Enteric-coated mycophenolate sodium: Therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S517-S520

  Sollinger, H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; ENTERIC COATED TABLET; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 1642282715     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.052     Document Type: Article

References (15)

1. Cecka JM, Terasaki PI (eds): In 16th Annual Volume Clinical Transplantation. Los Angeles, Calif.: UCLA Immunogenetics Center; 2000, p 481.
2. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321.
3. Sollinger H.W., US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225.
4. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029.
5. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 69:2000;2405.
6. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol. 11:2000;2366.
7. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 75:2003;1341.
8. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Aetiology, incidence and management. Drug Saf. 24:2001;645.
9. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 17:2003;200.
10. Knoll G.A., Macdonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 14:2003;2381.
11. Bjarnason I. Enteric coating of mycophenolate sodium a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc. 33:2001;3238.
12. Schmouder R, Arns W, Merkel F, et al: Pharmacokinetics of ERL080A: a new enteric coated formulation of mycophenolic acid-sodium. 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, 15-19 May 1999 (Abstract 787).
13. Budde K, Glander P, Hahn U, et al: Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients. Am J Transplant 2(suppl 3):399, 2002 (Abstract 1036).
14. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 4:2004;231.
15. Salvadori M. Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant Proc. 33:2001;3245.